TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03612544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (Vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT03027869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 15 minute anodal stimulation 1.5mA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 15 minute anodal stimulation 1.5mA

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 15 minute anodal stimulation 1.5mA
Study: NCT03649139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual immunotherapy drops
Description: artemisia annua (sweet sagewort) allergen extract drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: sublingual placebo drops
Study: NCT01352767

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPad
Description: Heating pad
Study: NCT00184067

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA 51

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Study: NCT02427893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobimetinib
Description: A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobimetinib
Description: A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
Study: NCT03655080

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Using the View Ray System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: * Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes
Study: NCT04308408

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Daily Amounts
Description: All food items displayed the corresponding GDA label in the lower left corner of the front of the package.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Traffic Light
Description: All food items displayed the corresponding MTL label in the lower left corner of the front of the package.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning Labels
Description: Food products were labeled with High in labels In the lower left corner of the front of the package. In total, 37 of the 60 food products in the shopping site did not display a WL.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants viewed a short (less than 1 min) video explaining how to interpret the label.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Participants viewed a short (less than 1 min) video explaining how to interpret the label.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video
Description: Participants viewed a short (less than 1 min) video explaining how to interpret the label.
Study: NCT03458988

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)
Description: Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
Study: NCT04666805

Intervention type: DRUG
Intervention: Letrozole
Description: Adjuvant therapy with letrozole for 5 years or until the disease relapses. Patients who have received tamoxifen adjuvant therapy for 5 years should continue to take Letrozole until the disease relapses. The recommended dose of Letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals. For patients with advanced breast cancer, treatment with Letrozole should continue until tumor progression is confirmed. Patients with liver and/or renal dysfunction (creatinine clearance rate ≥ 10 mL/min) do not need to adjust the dosage.

Intervention type: DRUG
Intervention: Exemestane
Description: The recommended dose of Exemestane for adult and older patients with early and advanced breast cancer is one 25 mg tablet administered orally once a day after a meal. After 2-3 years of tamoxifen treatment, patients with early breast cancer should continue to use Tamoxifen in the case of no recurrence or contralateral breast cancer, until the completion of 5-year sequential adjuvant therapy with tamoxifen and exemestane. Patients with advanced breast cancer should continue to take Exemestane until the tumor progresses.
Study: NCT03275519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to not receive prophylactic antibiotics after surgery.
Description: No antibiotics were ordered after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomization to receive prophylactic antibiotics after surgery
Description: In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
Study: NCT01017692

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
Study: NCT02278380

Intervention type: OTHER
Group type: OTHER
Intervention: Low GI Standard Breakfast
Description: Low GI Standard Breakfast

Intervention type: OTHER
Group type: OTHER
Intervention: Medium GI Standard Breakfast
Description: Medium GI Standard Breakfast

Intervention type: OTHER
Group type: OTHER
Intervention: Enfamama A+
Description: Nutritional pregnant milk supplement

Intervention type: OTHER
Group type: OTHER
Intervention: Glucerna Triple Care
Description: Nutritional product for diabetics

Intervention type: OTHER
Group type: OTHER
Intervention: Dumex Precima
Description: Pregnant and lactation women milk powder
Study: NCT02427893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemurafenib
Description: A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
Study: NCT01425281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Description: XIENCE implantation in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System
Description: ABSORB BVS implantation in the treatment of coronary artery disease.
Study: NCT04165785

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPT IPL
Description: Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham OPT IPL
Description: Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
Study: NCT01388764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
Study: NCT03116893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 After Standardised Breakfast
Description: High-fat high calorie breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administration of itraconazole together with BI 685509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administration of rifampicin together with BI 685509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 Fasted Conditions
Description: BI 685509, given alone
Study: NCT04561193

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT04579185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
Study: NCT01694030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attachment security priming

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attachment security priming
Study: NCT00292266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
Study: NCT03454776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloader One brace
Description: A knee brace used to unload affected compartments in osteoarthritic knees

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo brace
Description: A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
Study: NCT01050712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Synthetic Air
Description: Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
Study: NCT03391180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON Remineralization
Description: A material used for the Remineralization of white spot lesions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACPF
Description: Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
Study: NCT01186354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving results via genetic counselor
Description: participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
Study: NCT00531323

Intervention type: DRUG
Group type: OTHER
Intervention: TMC125 once daily
Description: Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily

Intervention type: DRUG
Group type: OTHER
Intervention: TMC125 twice daily
Description: Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
Study: NCT00735410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 dose of Split influenza vaccine
Study: NCT04388202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: FDA approved antidepressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: FDA approved antidepressant
Study: NCT03122769

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-metformin
Description: 200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
Study: NCT00923338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign (Vesico-vaginal fistula plug)
Description: Vesico-vaginal fistula plug
Study: NCT01616667

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: The patients included is operated with a total hip arthroplasty due to primary osteoarthritis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
Study: NCT01320904

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NMES
Description: We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closed Kinetic Chain
Description: During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
Study: NCT02278380

Intervention type: OTHER
Group type: OTHER
Intervention: Diasip
Description: Nutritional drinks for diabetics

Intervention type: OTHER
Group type: OTHER
Intervention: Test product
Description: Test product not patented yet
Study: NCT02717676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Episiotomy
Description: episiotomy will be done after crowning of the fetal head
Study: NCT01069094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 12.5 mg, administered as a once daily oral dose for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 25 mg, administered as a once daily oral dose for 90 days.
Study: NCT02197000

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DIM-Avail 100mg
Description: DIM 100 mg\*1 daily for 2 years
Study: NCT03053960

Intervention type: DEVICE
Intervention: Computed Tomography
Description: Undergo helical CT scan

Intervention type: DEVICE
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT scan
Study: NCT01069094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 50 mg, administered as a once daily oral dose for 90 days.
Study: NCT03053960

Intervention type: DEVICE
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT scan

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: PROCEDURE
Intervention: Therapeutic Conventional Surgery
Description: Undergo resection of tumor

Intervention type: PROCEDURE
Intervention: Histopathologic Examination
Description: Correlative studies
Study: NCT02279537

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study: NCT02864498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04309539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia.
Study: NCT01069094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucron Depot
Description: 3.75 mg IM monthly
Study: NCT04309539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined LFCN block with PENG block
Description: With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
Study: NCT01192516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Activity Pacing
Description: Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Activity Pacing
Description: Therapeutic intervention using generalized pacing instruction to manage symptoms
Study: NCT04189081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry mouth rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dry mouth rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water Control
Description: negative control
Study: NCT02244606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study: NCT01069094

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a once daily oral dose for 90 days.
Study: NCT02244606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Study: NCT04047745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
Study: NCT03293589

Intervention type: PROCEDURE
Intervention: open revascularization
Description: surgical revascularization (i.e. Bypass surgery)

Intervention type: PROCEDURE
Intervention: endovascular revascularization
Description: endovascular revascularization (stent, ballon angioplasty)
Study: NCT04191720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
Study: NCT02824952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagrisso
Description: taking orally everyday for 6 or 12 weeks.
Study: NCT02248103

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periosteal pedicle graft
Description: Autogenous pedicle graft harvested from the periosteum

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bioresorbable collagen membrane
Description: Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
Study: NCT01292434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag behavioral intervention
Description: Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
Study: NCT03312270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodality information comprehension
Description: Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
Study: NCT03493594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Description: online platform support, workshop, seminar and cooking demo etc